Related Experiment Video
Updated: Oct 25, 2025

10:12
Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
Published on: December 16, 2021
2.9K
ENTPD3 Marks Mature Stem Cell-Derived β-Cells Formed by Self-Aggregation In Vitro
Fiona M Docherty1, Kent A Riemondy2, Roberto Castro-Gutierrez1
1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
Diabetes
|August 12, 2021
Summary
Stem cell-derived beta-like cells (sBC) spontaneously mature in vitro into islet-like structures. A specific surface marker, ENTPD3, identifies the most mature cells for diabetes therapy development.
Area of Science:
- Endocrinology
- Stem Cell Biology
- Regenerative Medicine
Background:
- Stem cell-derived beta-like cells (sBC) offer potential for diabetes cell replacement therapy.
- Clinical application requires sBC to achieve functional maturity comparable to adult beta-cells.
- The process of human beta-cell maturation in vitro is not fully understood.
Purpose of the Study:
- To investigate spontaneous maturation events in stem cell-derived beta-like cells (sBC) in vitro.
- To identify markers for functionally mature sBC.
- To provide insights for developing mature sBC for diabetes therapy.
Main Methods:
- In vitro culture of sBC without exogenous maturation factors.
- Observation of self-enrichment into islet-like structures.
- Functional assays and surface protein analysis (ENTPD3/NDPTase3) to assess maturation.
Main Results:
- sBC spontaneously self-organized into islet-like cap structures in vitro.
- Self-enriched sBC (seBC) exhibited functional maturation.
- Distinct subpopulations with varying maturation levels were present within seBC.
- The surface protein ENTPD3 was identified as a specific marker for the most mature seBC population.
Conclusions:
- Spontaneous in vitro self-organization promotes functional maturation of sBC.
- ENTPD3 is a valuable marker for identifying and sorting mature sBC.
- These findings advance the development of functionally mature sBC for diabetes cell replacement therapy.

